Samsung Medical Center: Lymphoma trials

The registry lists 39 Lymphoma studies with Samsung Medical Center as lead sponsor. 2 are open to participants now and 1 have results posted.

Early Phase 1 1Phase 1 2Phase 2 18No phase 20(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study IVRecruitingNCT07032103
• Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study IIIRecruitingNCT03117036
• Concomitant Chemo-radiotherapy Plus VIDL Chemotherapy in NK/T-cell LymphomaCompletedNCT01007526Phase 2Results posted
• Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell TherapyActive, not recruitingNCT06552572Phase 2
• Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL)Status unknownNCT04127916
• Ibrutinib for Relapsed or Refractory Mantle Cell LymphomaCompletedNCT04061850
• Clinical Outcomes of Early-progressed Follicular Lymphoma in KoreaStatus unknownNCT04048395
• Genomic Evaluation in Patients With Diffuse Large B Cell Lymphoma After First Relapse/ProgressionStatus unknownNCT03977623
• Registry of BrentuximabVedotinin Patients With R/R Anaplastic Large Cell Lymphoma or Classical HLCompletedNCT03766516
• Phase II of Lenalidomide After Salvage Therapy in R/R Non-Hodgkin T-cell LymphomaStatus unknownNCT03730740Phase 2
• Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell LymphomaCompletedNCT03487133Phase 2
• Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]Status unknownNCT03439501Phase 2
• Pralatrexate for Relapsed or Refractory Peripheral T-cell LymphomaCompletedNCT03356678
• Intercontinental Cooperative Non-Hodgkin T-cell Lymphoma Prospective Registry StudyCompletedNCT02691351
• Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell LymphomaCompletedNCT02670616Phase 2
• VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)Status unknownNCT02544425Phase 2
• Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCLStatus unknownNCT02445404Phase 2
• Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell LymphomaCompletedNCT02424045Phase 2
• International Extranodal NK/T-cell Lymphoma ProjectCompletedNCT02386813
• Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin LymphomasCompletedNCT02280785Phase 2
• Epstein-Barr Virus Status in Diffuse Large B Cell LymphomaCompletedNCT02060435
• Bortezomib Maintenance in High Risk DLBCLStatus unknownNCT01965977Phase 2
• Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell LymphomaCompletedNCT01965119Phase 2
• A Pilot Study of Romidepsin in Relapsed or Refractory Extranodal NK/T-cell LymphomaCompletedNCT01913119Early Phase 1
• Samsung Medical Center-Lymphoma Cohort Study-IICompletedNCT01877109
• p-AKT Expression on Clinical Outcomes in Malignant LymphomaCompletedNCT01789060
• Gemcitabine in NK/T Cell LymphomaCompletedNCT01660568
• Treatment Resistance Related With Gene Expression Profile of Diffuse Large B-cell LymphomaCompletedNCT01606605
• Retrospective Analysis of Skin/Soft Tissue Primary NK/T Cell LymphomaCompletedNCT01341119
• Factors Influencing Hepatitis B Virus Reactivation in Lymphoma Patients Treated With RituximabCompletedNCT01311232
• Concomitant Chemo-radiotherapy Followed by MIDLE Chemotherapy in Stage I/II Extranodal NK/T-cell LymphomaCompletedNCT01238159Phase 2
• Prospective Cohort Study With Central Nervous System Evaluation in Diffuse Large B-cell LymphomaCompletedNCT01202448Not applicable
• RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell LymphomasCompletedNCT01198665Phase 1/2
• High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 StudyCompletedNCT01083342Phase 2
• Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)CompletedNCT01054781Phase 2
• Multicenter Cross Sectional Study of Primary Intestine LymphomaCompletedNCT01043302
• Samsung Medical Center-Lymphoma Cohort StudyCompletedNCT00822731Not applicable
• Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)/T-cell LymphomaCompletedNCT00418535Phase 2
• Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell LymphomasCompletedNCT00374699Phase 1/2